ArticleCancers2020
Pre-Existing Tumoral B Cell Infiltration and Impaired Genome Maintenance Correlate with Response to Chemoradiotherapy in Locally Advanced Rectal Cancer.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Integrated Bioinformatic and Experimental Analysis ofBiomedicines · 2026Article
- Identification of an Immune Cell Gene Signature for Predicting Response and Prognosis in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.Cancer medicine · 2026Article
- Expression Profiles and Biomarker Potential of Long Non-Coding RNAs H19, NEAT1, MALAT1 and HOTAIR in Locally Advanced Rectal Cancer Patients.International journal of molecular sciences · 2026Article
- Integrating single-cell and bulk transcriptomes identifies B cell features associated with neoadjuvant chemoradiotherapy sensitivity in rectal cancer.Scientific reports · 2026Article
- Article
- B cells and tertiary lymphoid structures in cancer therapy response.BJC reports · 2025Review
- Increased LACTB2 Expression Regulates Oxidative Phosphorylation and mTORC1 Signaling of Colorectal Cancer.Molecular biotechnology · 2025Article
- Radioresistance in rectal cancer: can nanoparticles turn the tide?Molecular cancer · 2025Review
- Integrated genomic and clinical modeling for prognostic assessment of radiotherapy response in rectal neoplasms.Open life sciences · 2025Article
- An immune-related gene prognostic prediction risk model for neoadjuvant chemoradiotherapy in rectal cancer using artificial intelligence.Frontiers in oncology · 2024Article
- Research on radiotherapy related genes and prognostic target identification of rectal cancer based on multi-omics.Journal of translational medicine · 2023Article
- Review
- Human gene and microbial analyses in rectal cancer complete responses to radiotherapy.BJS open · 2023Article
- CD11cOncoimmunology · 2023Article
- Exome and Tissue-Associated Microbiota as Predictive Markers of Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer.Frontiers in oncology · 2022Article
- Article
- Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer.Frontiers in oncology · 2021Article
- Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer.World journal of gastroenterology · 2020Article
- Landscape of B lymphocytes and plasma cells in digestive tract carcinomas.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 1 country.
Funding
Abstract
Locally advanced rectal cancer (LARC) remains a medical challenge. Reliable biomarkers to predict which patients will significantly respond to neoadjuvant chemoradiotherapy (nCRT) have not been identified. We evaluated baseline genomic and transcriptomic features to detect differences that may help predict response to nCRT. Eligible LARC patients received nCRT (3D-LCRT 50.4 Gy plus capecitabine 825 mg/m2/bid), preceded by three cycles of CAPOX in high systemic-relapse risk tumors, and subsequent surgery. Frozen tumor biopsies at diagnosis were sequenced using a colorectal cancer panel. Transcriptomic data was used for pathway and cell deconvolution inferential algorithms, coupled with immunohistochemical validation. Clinical and molecular data were analyzed according to nCRT outcome. Pathways related to DNA repair and proliferation (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.